Detalles de la búsqueda
1.
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
Diabetes Obes Metab
; 26(2): 540-547, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37880868
2.
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.
Diabetes Obes Metab
; 25(2): 545-555, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36263928
3.
A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes.
Diabetes Obes Metab
; 23(3): 674-681, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33236518
4.
Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trial.
EClinicalMedicine
; 68: 102430, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38545092
5.
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial.
J Diabetes Sci Technol
; : 19322968241232709, 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38420944
6.
In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin Pumps.
J Pharm Sci
; 112(4): 963-973, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36521561
7.
A Bayesian approach for inference from a bridging study with binary outcomes.
J Biopharm Stat
; 22(5): 935-51, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22946941
8.
Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy.
Indian J Endocrinol Metab
; 26(4): 354-361, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36185965
9.
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin.
Diabetes Ther
; 13(7): 1299-1310, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35650350
10.
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M).
Diabetes Ther
; 13(5): 1053-1071, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35420397
11.
Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin.
Diabetes Ther
; 12(2): 557-568, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33432547
12.
InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design.
Diabetes Ther
; 11(4): 1017-1027, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32100192
13.
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design.
Diabetes Ther
; 11(7): 1607-1608, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32361833
14.
Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design.
Diabetes Ther
; 11(8): 1907-1908, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32578133
15.
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial.
Diabetes Technol Ther
; 22(9): 666-673, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31833801
16.
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Diabetes Technol Ther
; 22(7): 516-526, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32068436
17.
Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Diabetes Technol Ther
; 22(2): 85-95, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31804851
18.
Accelerated test system strength models based on Birnbaum-Saunders distribution: a complete Bayesian analysis and comparison.
Lifetime Data Anal
; 15(3): 379-96, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19255842
19.
Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model.
PLoS One
; 13(6): e0197478, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29874257
Resultados
1 -
19
de 19
1
Próxima >
>>